Carbylan Therapeutics, Inc. (NASDAQ: CBYL) was established in 2004 and is headquartered in Palo Alto, California. The company’s predecessor was Carbylan Biosurgery, Inc. It was changed to its current company name in March 2014. CBYL is a clinical-stage pharmaceutical company that treats joint pain. 14 full-time employees.
Carbylan is a professional biopharmaceutical company focusing on the combination, development and commercial application of new and old therapies for arthritis. The main product, HYDROS-TA, has completed Phase IIB clinical trials, which can quickly and continuously link pain symptoms caused by osteoarthritis.
Carbylan (CYBL) investment:
Carbylan on 2015-04-09 on the Nasdaq under the ticker symbol CYBL, the issue price of 5 US dollars / common stock, the current market value of $ 92.87 million. Generally speaking, completion of clinical IIb trials often has a higher chance of success. You can refer to SMMT and CHEK for attention.
Company official website: http://www.carbylan.com/
Yahoo Finance: http://finance.yahoo.com/q?s=CBYL
American House: https://www.thisyear.com/cbyl.html